Axerion Seeks New Answers in Spinal Cord Injury, Alzheimer's

Privately held Axerion Therapeutics Inc. hopes to translate two technologies exclusively licensed from Yale University into revolutionary therapeutics in a pair of indications – spinal cord injury (SCI) and Alzheimer's disease (AD) – that have bedeviled biotechs and big pharmas, alike.